SCHEMBL5145537

SCHEMBL5145537

CCOC(=O)N1CCC(Oc2cccc(NC(=O)c3cc(C(F)(F)F)ccc3-c3ccccc3)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.52
HTT P42858 1/20 0.52
TRPV4 Q9HBA0 5/20 0.45
EPHX2 P34913 1/20 0.45
SCN10A Q9Y5Y9 1/20 0.44
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CHRM3 P20309 1/20 0.43
APOB P04114 1/20 0.42
MTTP P55157 1/20 0.42
CSF1R P07333 1/20 0.42
PDGFRB P09619 1/20 0.42
KIT P10721 1/20 0.42
DDR1 Q08345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3289889 0.93 MAPT (0.45) SMN1; SMN2MAPTHTTTRPV4EPHX2
SCHEMBL5144167 0.93 KDM4E (0.48) SMN1; SMN2MAPTHTTTRPV4EPHX2
SCHEMBL3290189 0.91 SMN1; SMN2 (0.51) SMN1; SMN2MAPTHTTKDM4EGAA
SCHEMBL3289775 0.90 POLB (0.51) MAPTTRPV4EPHX2SCN10AKDM4E
SCHEMBL3289503 0.90 EPHX2 (0.49) MAPTTRPV4EPHX2SCN10AKDM4E
SCHEMBL3288593 0.90 SMN1; SMN2 (0.44) SMN1; SMN2MAPTHTTEPHX2KDM4E
SCHEMBL3292088 0.84 MTTP (0.48) SMN1; SMN2MAPTHTTKDM4EGAA
SCHEMBL3291608 0.84 SMO (0.46) SMN1; SMN2MAPTHTTEPHX2KDM4E
SCHEMBL3292142 0.83 MTTP (0.52) SMN1; SMN2MAPTKDM4EGAAALDH1A1
SCHEMBL5145637 0.83 F10 (0.48) TRPV4SCN10AKDM4EGAAAPOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254919-A1 Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems MERCK PATENT GMBH (DE) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254919-A1 Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems GPR119, FABP4, LIPC SMN1; SMN2 4852/4885MAPT 4285/4885HTT 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.